Atopic Dermatitis
A Managed Access Protocol (MAP) is in place for medicines for the treatment of severe and moderate-to-severe atopic dermatitis. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of abrocitinib (Cibinqo®), dupilumab (Dupixent®), tralokinumab (Adtralza®) or upadacitinib (RINVOQ®) under the High Tech Arrangement.
Applications for reimbursement approval of abrocitinib (Cibinqo®), dupilumab (Dupixent®), tralokinumab (Adtralza®) and upadacitinib (RINVOQ®) for the treatment of severe and moderate-to-severe atopic dermatitis under the High Tech Arrangement will only be considered from consultant dermatologists with a specialist registration in dermatology, registered with the Irish Medical Council, practising in the healthcare system in the Republic of Ireland, and who have agreed to the terms of the MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the HSE-Managed Access Protocol for high tech medicines for the treatment of atopic dermatitis can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.